International Clinics
Daily
FDA grants accelerated approval to dostarlimab for dMMR/MSI-H locally advanced rectal cancer
On 19 October 2026 the FDA granted accelerated approval to Jemperli (dostarlimab) for stage II/III locally advanced rectal cancer.

